Skip to main content

Noema Pharma raises 103 million Swiss francs from investors

| News

Noema Pharma raises 103 million Swiss francs from investors


Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round. The Basel-based biotech firm, which specializes in the area of debilitating diseases of the central nervous system, will use this fresh capital injection to advance its clinical-phase products.

Noema Pharma has successfully closed a Series B financing round. The biotech firm was able to raise gross proceeds in the amount of 103 million Swiss francs from both existing and new investors, further details of which can be found in a press release. The financing round was led by the European investment firms Forbion and Jeito Capital. Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will now join the Board of Directors of Noema Pharma.

Noema Pharma specializes in debilitating diseases of the central nervous system. The proceeds from this financing round will be used to advance Noema’s clinical-stage product candidates. These include the lead product basimglurant for severe pain in trigeminal neuralgia and seizures related to tuberous sclerosis. Investigations into a drug for the treatment of Tourette’s syndrome and stuttering are also in progress.

Very encouraging clinical data

Nanna Lüneborg, General Partner at Forbion, believes this is the right time for an investment due to the fact that the company “has started to generate very encouraging clinical data in indications of high unmet need”. This applies in particular to the lead product basimglurant.

Noema Pharma was founded in 2019 following a seed investment from the Paris-based venture capital firm Sofinnova Partners and four clinical-stage products in-licensed by Roche. According to Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, the company is “incredibly proud” of everything that Noema Pharma has achieved since its inception. The current capital increase comes on the back of a Series A financing round closed in December 2020, in which the company raised a total of 54 million Swiss francs (converted from US dollars). This was also led by Sofinnova Partners together with Polaris Partners from the USA.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.